Saving time and money The resources required to bring a new drug to market are as well-known as they are staggering: upwards of $1.3 billion in costs, 10 to 15 years from target selection to approval, and an overall failure rate approaching 95%.
Author: Vassilis Virvilis
Biovista to present at the Drug Repositioning Conference
CHARLOTTESVILLE, Virginia, June 3, 2011 — Biovista announced today that it is presenting at the Drug Repositioning Conference, San Francisco, on July 13 2011. Biovista’s President, Dr. Aris Persidis, will give a presentation on systematic repositioning using Mechanism of Action. The Drug Repositioning Conference is one of the prime events in this space and has been … Read More
BioWorld: Repurposing: Achilles Heel or Extra Leg to Stand On?
By Anette Breind, BioWorld Insight For Academia or Industry In the private space, Charlottesville, Va.-based Biovista Inc…Biovista has a positioning program that uses a bioinformatics approach to “develop all reasonable opportunities” for a drug, Persidis said, by tracking “without bias,” all biological effects of a compound…But Biovista is also developing its own in-house pipeline of existing … Read More
Biovista Announces Research Collaboration With a Major Pharmaceutical Company
CHARLOTTESVILLE, Virginia, April 27, 2011 /PRNewswire/ — Biovista announced today that it has entered into a research collaboration agreement with Novartis. The collaboration is focused on identifying new indications for a number of undisclosed Novartis compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. The terms of the agreement include an upfront payment and success-based … Read More
Biovista to present at the 5th World Generic Medicines Congress
CHARLOTTESVILLE, Virginia, February 11, 2011 — Biovista announced today that it is presenting at the 5th World Generic Medicines Congress, London UK, on Thursday 24 February 2011. Biovista’s CEO, Dr. Andreas Persidis, will give a presentation on the business and science of repositioning generic medicines at the 5th annual World Generic Medicines Congress Europe of … Read More

